Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
FGFR4 inhibitor
DRUG CLASS:
FGFR4 inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
erdafitinib (70)
BLU-554 (4)
H3B-6527 (3)
FGF401 (3)
ABSK012 (1)
BLU 9931 (1)
ABSK011 (1)
ASP5878 (0)
INCB62079 (0)
LY2874455 (0)
SY-4798 (0)
U3-1784 (0)
erdafitinib (70)
BLU-554 (4)
H3B-6527 (3)
FGF401 (3)
ABSK012 (1)
BLU 9931 (1)
ABSK011 (1)
ASP5878 (0)
INCB62079 (0)
LY2874455 (0)
SY-4798 (0)
U3-1784 (0)
›
Associations
(83)
News
Trials
VERI cancer hierarchy
Reset Filters
FGFR2 mutation
Urothelial Cancer
FGFR2 mutation
Urothelial Cancer
erdafitinib
Sensitive: A1 - Approval
erdafitinib
Sensitive
:
A1
erdafitinib
Sensitive: A1 - Approval
erdafitinib
Sensitive
:
A1
FGFR3 mutation
Urothelial Cancer
FGFR3 mutation
Urothelial Cancer
erdafitinib
Sensitive: A1 - Approval
erdafitinib
Sensitive
:
A1
erdafitinib
Sensitive: A1 - Approval
erdafitinib
Sensitive
:
A1
FGFR mutation
Urothelial Cancer
FGFR mutation
Urothelial Cancer
erdafitinib
Sensitive: A2 - Guideline
erdafitinib
Sensitive
:
A2
erdafitinib
Sensitive: A2 - Guideline
erdafitinib
Sensitive
:
A2
No biomarker
Bladder Cancer
No biomarker
Bladder Cancer
erdafitinib
Sensitive: A2 - Guideline
erdafitinib
Sensitive
:
A2
erdafitinib
Sensitive: A2 - Guideline
erdafitinib
Sensitive
:
A2
FGFR2 fusion
Urothelial Cancer
FGFR2 fusion
Urothelial Cancer
erdafitinib
Sensitive: B - Late Trials
erdafitinib
Sensitive
:
B
erdafitinib
Sensitive: B - Late Trials
erdafitinib
Sensitive
:
B
FGFR3 fusion
Urothelial Cancer
FGFR3 fusion
Urothelial Cancer
erdafitinib
Sensitive: B - Late Trials
erdafitinib
Sensitive
:
B
erdafitinib
Sensitive: B - Late Trials
erdafitinib
Sensitive
:
B
FGFR3 mutation
Cholangiocarcinoma
FGFR3 mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
FGFR2 mutation
Cholangiocarcinoma
FGFR2 mutation
Cholangiocarcinoma
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
FGFR2 mutation
Gastric Cancer
FGFR2 mutation
Gastric Cancer
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
FGFR3 mutation
Gastric Cancer
FGFR3 mutation
Gastric Cancer
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
FGFR3 mutation
Solid Tumor
FGFR3 mutation
Solid Tumor
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
FGFR2 mutation
Solid Tumor
FGFR2 mutation
Solid Tumor
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
FGFR3 mutation
Bladder Cancer
FGFR3 mutation
Bladder Cancer
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
FGFR2 mutation
Bladder Cancer
FGFR2 mutation
Bladder Cancer
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
erdafitinib
Sensitive: C1 - Off-label
erdafitinib
Sensitive
:
C1
FGF19 overexpression
Hepatocellular Cancer
FGF19 overexpression
Hepatocellular Cancer
ABSK011
Sensitive: C2 – Inclusion Criteria
ABSK011
Sensitive
:
C2
ABSK011
Sensitive: C2 – Inclusion Criteria
ABSK011
Sensitive
:
C2
FGFR mutation
Urothelial Cancer
FGFR mutation
Urothelial Cancer
erdafitinib + JNJ-63723283
Sensitive: C3 – Early Trials
erdafitinib + JNJ-63723283
Sensitive
:
C3
erdafitinib + JNJ-63723283
Sensitive: C3 – Early Trials
erdafitinib + JNJ-63723283
Sensitive
:
C3
FGFR3-BAIAP2L1 fusion
Urothelial Cancer
FGFR3-BAIAP2L1 fusion
Urothelial Cancer
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
ER positive + FGFR3 amplification
HER2 Negative Breast Cancer
ER positive + FGFR3 amplification
HER2 Negative Breast Cancer
palbociclib + erdafitinib
Sensitive: C3 – Early Trials
palbociclib + erdafitinib
Sensitive
:
C3
palbociclib + erdafitinib
Sensitive: C3 – Early Trials
palbociclib + erdafitinib
Sensitive
:
C3
ER positive + FGFR1 amplification
HER2 Negative Breast Cancer
ER positive + FGFR1 amplification
HER2 Negative Breast Cancer
palbociclib + erdafitinib
Sensitive: C3 – Early Trials
palbociclib + erdafitinib
Sensitive
:
C3
palbociclib + erdafitinib
Sensitive: C3 – Early Trials
palbociclib + erdafitinib
Sensitive
:
C3
FGFR1 fusion
Cholangiocarcinoma
FGFR1 fusion
Cholangiocarcinoma
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR3 R248C
Urothelial Cancer
FGFR3 R248C
Urothelial Cancer
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR2-BICC1 fusion
Urothelial Cancer
FGFR2-BICC1 fusion
Urothelial Cancer
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR3 S249C
Urothelial Cancer
FGFR3 S249C
Urothelial Cancer
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR3 G370C
Urothelial Cancer
FGFR3 G370C
Urothelial Cancer
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR3 Y373C
Urothelial Cancer
FGFR3 Y373C
Urothelial Cancer
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR2-CASP7 fusion
Urothelial Cancer
FGFR2-CASP7 fusion
Urothelial Cancer
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGF19 positive
Hepatocellular Cancer
FGF19 positive
Hepatocellular Cancer
BLU-554
Sensitive: C3 – Early Trials
BLU-554
Sensitive
:
C3
BLU-554
Sensitive: C3 – Early Trials
BLU-554
Sensitive
:
C3
FGF19 negative
Hepatocellular Cancer
FGF19 negative
Hepatocellular Cancer
BLU-554
Resistant: C3 – Early Trials
BLU-554
Resistant
:
C3
BLU-554
Resistant: C3 – Early Trials
BLU-554
Resistant
:
C3
FGF19 overexpression
Hepatocellular Cancer
FGF19 overexpression
Hepatocellular Cancer
BLU-554
Sensitive: C3 – Early Trials
BLU-554
Sensitive
:
C3
BLU-554
Sensitive: C3 – Early Trials
BLU-554
Sensitive
:
C3
FGFR3-TACC3 fusion
Glioblastoma
FGFR3-TACC3 fusion
Glioblastoma
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR fusion
Urothelial Cancer
FGFR fusion
Urothelial Cancer
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
FGFR2-BICC1 fusion
Endometrial Cancer
FGFR2-BICC1 fusion
Endometrial Cancer
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
erdafitinib
Sensitive: C3 – Early Trials
erdafitinib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login